A new trading day began on Tuesday, with Adma Biologics Inc (NASDAQ: ADMA) stock price up 4.46% from the previous day of trading, before settling in for the closing price of $16.61. ADMA’s price has ranged from $5.88 to $23.64 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 71.73% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 43.56%. With a float of $228.00 million, this company’s outstanding shares have now reached $236.62 million.
In an organization with 624 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 51.4%, operating margin of 32.59%, and the pretax margin is 29.48%.
Adma Biologics Inc (ADMA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.55%, while institutional ownership is 86.69%. The most recent insider transaction that took place on Nov 22 ’24, was worth 317,250. In this transaction CFO and Treasurer of this company sold 15,000 shares at a rate of $21.15, taking the stock ownership to the 199,433 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO sold 48,967 for $21.10, making the entire transaction worth $1,033,204. This insider now owns 1,989,007 shares in total.
Adma Biologics Inc (ADMA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 43.56% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Here are Adma Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.62. Likewise, its price to free cash flow for the trailing twelve months is 51.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.81, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.99 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.2 million. That was better than the volume of 2.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.54%. Additionally, its Average True Range was 0.99.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 37.97%, which indicates a significant decrease from 81.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.46% in the past 14 days, which was lower than the 58.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.69, while its 200-day Moving Average is $16.16. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $17.89. Second resistance stands at $18.44. The third major resistance level sits at $19.12. If the price goes on to break the first support level at $16.66, it is likely to go to the next support level at $15.98. Assuming the price breaks the second support level, the third support level stands at $15.43.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
With a market capitalization of 4.10 billion, the company has a total of 236,390K Shares Outstanding. Currently, annual sales are 426,450 K while annual income is 197,670 K. The company’s previous quarter sales were 117,550 K while its latest quarter income was 111,900 K.
